Cargando…

A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer

BACKGROUND: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. METHODS: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Alexander J., Samson, Pamela, DeWees, Todd, Henke, Lauren, Baranski, Thomas, Schwarz, Julie, Pfeifer, John, Grigsby, Perry, Markovina, Stephanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346248/
https://www.ncbi.nlm.nih.gov/pubmed/30552739
http://dx.doi.org/10.1002/cam4.1857
_version_ 1783389727090540544
author Lin, Alexander J.
Samson, Pamela
DeWees, Todd
Henke, Lauren
Baranski, Thomas
Schwarz, Julie
Pfeifer, John
Grigsby, Perry
Markovina, Stephanie
author_facet Lin, Alexander J.
Samson, Pamela
DeWees, Todd
Henke, Lauren
Baranski, Thomas
Schwarz, Julie
Pfeifer, John
Grigsby, Perry
Markovina, Stephanie
author_sort Lin, Alexander J.
collection PubMed
description BACKGROUND: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. METHODS: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho‐MEK, MAPK(dpERK), PPARγ, and phospho‐AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. RESULTS: A total of 231 patients had archived formalin‐fixed, paraffin‐embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6‐82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22‐0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET‐negative and either MAPK(dpERK)‐positive or pAKT‐positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5‐11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3‐6.0). CONCLUSION: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone.
format Online
Article
Text
id pubmed-6346248
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63462482019-01-29 A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer Lin, Alexander J. Samson, Pamela DeWees, Todd Henke, Lauren Baranski, Thomas Schwarz, Julie Pfeifer, John Grigsby, Perry Markovina, Stephanie Cancer Med Cancer Prevention BACKGROUND: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. METHODS: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho‐MEK, MAPK(dpERK), PPARγ, and phospho‐AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. RESULTS: A total of 231 patients had archived formalin‐fixed, paraffin‐embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6‐82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22‐0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET‐negative and either MAPK(dpERK)‐positive or pAKT‐positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5‐11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3‐6.0). CONCLUSION: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone. John Wiley and Sons Inc. 2018-12-14 /pmc/articles/PMC6346248/ /pubmed/30552739 http://dx.doi.org/10.1002/cam4.1857 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Prevention
Lin, Alexander J.
Samson, Pamela
DeWees, Todd
Henke, Lauren
Baranski, Thomas
Schwarz, Julie
Pfeifer, John
Grigsby, Perry
Markovina, Stephanie
A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
title A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
title_full A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
title_fullStr A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
title_full_unstemmed A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
title_short A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
title_sort molecular approach combined with american thyroid association classification better stratifies recurrence risk of classic histology papillary thyroid cancer
topic Cancer Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346248/
https://www.ncbi.nlm.nih.gov/pubmed/30552739
http://dx.doi.org/10.1002/cam4.1857
work_keys_str_mv AT linalexanderj amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT samsonpamela amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT deweestodd amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT henkelauren amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT baranskithomas amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT schwarzjulie amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT pfeiferjohn amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT grigsbyperry amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT markovinastephanie amolecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT linalexanderj molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT samsonpamela molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT deweestodd molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT henkelauren molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT baranskithomas molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT schwarzjulie molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT pfeiferjohn molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT grigsbyperry molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer
AT markovinastephanie molecularapproachcombinedwithamericanthyroidassociationclassificationbetterstratifiesrecurrenceriskofclassichistologypapillarythyroidcancer